cyrilzakka/clinical-trials huggingface dataset:
Ghrelin Levels in Early IVF Pregnancies

In this study, we have assessed the potential prognostic value for gestational outcome of maternal ghrelin levels at very early stages of IVF pregnancies. In addition, ghrelin responses to meal intake were explored at early gestation.

Ghrelin is a pleiotropic hormone recently involved in the control of growth and metabolism, whose circulating levels fluctuate in relation to food intake and body mass index. Ghrelin has been detected in the decidualized endometrium, as well as in human and rat placenta, with a distinctive temporal pattern of expression along pregnancy.

Comparison(s): A total of 106 patients undergoing IVF procedures were prospectively recruited. On d-16 and 23 after oocyte retrieval, the patients were subjected to blood sampling after overnight fasting, for determination of serum ghrelin, hCG and progesterone levels. In addition, ghrelin levels were assayed in these groups, 2-h after ingestion of a fixed-calorie meal.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing IVF
Effect on Weight Loss of Exenatide Versus Placebo

This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin, sulfonylurea, or metformin plus a sulfonylurea. Subjects will be treated with exenatide or placebo in addition to their current oral antidiabetes agent regimen and participate in a lifestyle modification program.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with type 2 diabetes for at least 6 months
* Have been treated with a stable dose of the following for at least 6 weeks prior to screening: \*immediate or extended release metformin, or \*a sulfonylurea, or \*a fixed-dose sulfonylurea/metformin combination therapy
* Have an HbA1c of 6.6% to 10.0%, inclusive
* Have a Body Mass Index (BMI) of 25 kg/m\^2 to 39.9 kg/m\^2, inclusive

Exclusion Criteria:

* Are treated with any of the following excluded medications: \*exogenous insulin, thiazolidinedione, or alpha-glucosidase inhibitor for more than 1 week within 6 weeks of screening; \*Symlin injection at any time; \* Byetta injection within 3 months of screening or discontinuation of therapy at any time due to adverse reaction; \*drugs that directly affect gastrointestinal motility; \*use of a weight loss drug (including those available over the counter) within 3 months of screening; \*chronic (lasting longer than 2 weeks) systemic corticosteroids (excluding topical, intranasal, and inhaled preparations) by oral, intravenous, or intramuscular route within 2 months of screening
* Have conditions contraindicating metformin and/or sulfonylurea use
* Have had a change in lipid-lowering agents within 6 weeks of screening
* Have received glucagon-like peptide-1 (GLP-1) analogs, or dipeptidyl peptidase-IV inhibitors (DPP-IV inhibitors) or have previously participated in this study
* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
Comparison of Different Low Volume Solutions Prior to Colonoscopy

Study evaluates the head -to-head efficacy and tolerability of low volume preparations prior to colonoscopy

Aim of the study: To compare the efficacy and tolerance of sodium picosulphate/magnesium citrate, polyethylene glycol/ascorbic acid and oral sulfate formula in a single or split dose regimen prior to colonoscopy

Eligibility Criteria:
Inclusion Criteria:

* subjects referred to diagnostic or therapeutic colonoscopy

Exclusion Criteria:

* known or suspected bowel obstruction
* active bowel inflammation
* pregnancy
* prior bowel resection
* any presence of serious medical conditions ( cardiac, renal, liver disease)
* inability to obtain valid data from subject
* active bowel bleeding
Effects of Insoles in Patients With Rheumatoid Arthritis: Randomized Controlled Trial.

Deformity and foot pain is nearly omnipresent (90%) in rheumatoid arthritis (RA), due to the interaction between inflammation and abnormal biomechanical. These cause instability in the hindfoot, which cause deformity of the forefoot, and they cause more pressure on the plantar forefoot and more pain during daily activities. Non-pharmacological interventions (insole, footwear) have an important role, reducing pain and disability, increasing the effectiveness and improving daily activities.

Randomized double-blind clinical trial. Two samples of patients will be taken: the control group, which will consist of patients with rheumatoid arthritis and standardized insoles, and other group, which will consist of patients with rheumatoid arthritis and insoles made with direct adaptation technique (TAD) and patients with rheumatoid arthritis and insoles made with an scanner (CAD-CAM). The variables that the investigators will measure are: age, sex, study level, current occupation, rheumatoid arthritis evolution time, quality of life and physical function, pain and health level and general function of the foot. The investigators will use: an accelerometer, and questionnaires: Foot and Ankle Ability Measures (FAAM), Manchester foot pain and disability index (MFPDI), Medical outcomes study short form-36 (SF-36) y Foot Function Index (FFI). This study will analyze patients in the Universities of Malaga and Salford for 6 months.

Eligibility Criteria:
Inclusion Criteria:

* More than 18 years of age
* Early RA
* To meet the criteria of American College of Rheumatology
* History of bilateral subtalar and/or ankle and/or talonavicular pain
* Informed consent
* Normal range of motions at the ankle, subtalar, and midtarsal joints.

Exclusion Criteria:

* Concomitant musculoskeletal disease
* Central or peripheral nervous system disease
* Endocrine disorders, especially diabetes mellitus with a level of insufficient foot sensitivity
* Patients with a history of orthopedic foot surgery
* Those currently using foot orthoses.
* Patients with foot trauma in the last 6 months previous to the study
* Vascular diseases affecting the foot, active synovitis and edema.
* Normal daily walking aids will be not permitted.
Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing Therapy for PD-related Voice/Speech Impairment

This study will compare group singing to group speech therapy without singing. You may be eligible for this study if you have been diagnosed with PD for one year or more and you have a quiet voice or difficulty being understood.

The National Parkinson Foundation Center of Excellence at Beth Israel Deaconess Medical Center is conducting a research study to test whether group singing therapy helps people with voice or speech disorders due to Parkinson's disease (PD). Communication problems, including loss of vocal loudness, affect many people with PD. While existing forms of speech therapy have been shown to be helpful, group singing may be a beneficial alternative to traditional speech therapy.

The study will involve participating in weekly treatment sessions where subjects will receive training in vocal exercises from a speech-language pathologist with expertise in PD, as well as instructions for structured home practice. Participants will be assigned to a singing or non-singing group for the 12-week treatment phase of the study. Researchers will measure subjects' vocal function and communication-related quality of life before and several times after the 12-week program. All subjects and their care partners are welcome to participate in a singing group following the study.

You may be eligible for this study if you have been diagnosed with PD for one year or more, and you have difficulty with your voice or speech such as quiet voice, or difficulty being understood.

Eligibility Criteria:
Inclusion Criteria:

* Difficulty being heard or understood
* Diagnosis of Parkinson's Disease for one year

Exclusion Criteria:

* No other neurological conditions(i.e. stroke, cerebellar ataxia) that affect voice quality
* No history of vocal chord hemorrhage
The Effect Of Core Stability Training In Temporomandibular Disorders

This study is to investigate the effect of Core stability training on pain, function, quality of life, sleep quality, body posture, foot posture, oral habits and kinesiophobia in individuals with temporomandibular disorder.

Materials and Methods: The study included 40 people over the age of 18, who were diagnosed with temporomandibular disorder from the dentist.


Eligibility Criteria:
Inclusion Criteria:

* Male and female patients aged 18-55, diagnosed with temporomandibular disease by a dentist

Exclusion Criteria:

* Having received another treatment for TMR other than the use of night plate in the last 6 months
* Having a disease that can cause facial pain such as sinusitis, migraine, tension headache, trigeminal neuralgia
* Skeletal system fractures
Evaluation of Effects of Bracket's Slot System on the Quantity and Quality of Teeth Movements During Orthodontic Leveling and Alignment Stage

Evaluation of effect of bracket slot system on the quality and quantity of tooth movement during leveling and alignment stage


Eligibility Criteria:
Inclusion Criteria:

* An age range from14 to18 years. All permanent teeth are erupted(3rd molar not included).
* Angle class I malocclusion with normal facial proportions.
* Moderate to severe crowding in the lower dental arch asassessed by lett irregularity Index that require treatment with fixed appliance using extraction approach.
* There is no previous orthodontic treatment.

Exclusion Criteria:

* Poor oral hygiene or periodontally compromised teeth.
* Craniofacial anomalies or previous history of trauma, bruxism, or Parafunctions.
* Uncooperativepatient.
Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration

The purpose of this collaboration is to establish a multi-modality image database including coronary angiograms, optical coherence tomography (OCT), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. The main goal of this collaboration is to create a resource to promote further understanding of the pathobiology of atherosclerosis through image analysis.

The purpose of this collaboration is to establish a multi-modality image database including coronary angiograms, optical coherence tomography (OCT), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. About one thousand patients who underwent coronary angiography with OCT and had a CTA prior to catheterization at Tsuchiura Kyodo General Hospital (TKGH) in Japan, will be included. A subset of these patients also had CMR. The main goal of this collaboration is to create a resource to promote further understanding of the pathobiology of atherosclerosis through image analysis.

Eligibility Criteria:
Inclusion Criteria:

* Had CTA prior to cardiac catheterization and then OCT during catheterization

Exclusion Criteria:

-
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Primary Objective:

To describe the safety of the 2004-2005 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule (described in the package insert for vaccine-naïve young children) to the investigational and control groups.

Observational Objective:

To describe the percentage of protective Hemagglutination Inhibition (HAI) antibody titers (following a 2-dose Fluzone® immunization series) to each of the 3 vaccine antigens among the investigational and control groups.

This is an observational and descriptive study that will provide preliminary comparative information about the safety and immunogenicity of Fluzone® vaccine among children aged 6 to 12 weeks (the investigational group, also referred to as the 2-month-old group) versus children aged 24 to 36 weeks (the control group, also referred to as the 6-month-old group). The study is not designed to achieve any preset statistical power, and no hypotheses will be tested.

Eligibility Criteria:
Inclusion Criteria :

* Aged 42 to 84 days (6 to 12 weeks) or 24 to 36 weeks on the day of inclusion.
* Born at full term of pregnancy (≥ 36 weeks) with a birth weight ≥ 2.5 kg.
* Considered to be in good health on the basis of reported medical history and history-directed physical examination.
* Available for the duration of the study.
* Parent/guardian willing and able to provide informed consent.
* Parent/guardian able to attend all scheduled visits and comply with all trial procedures.
* Willingness to permit venipuncture or heel stick for purposes of collecting a blood sample.

Exclusion Criteria :

* Reported allergy to egg proteins, chicken proteins or any other constituent of the vaccine.
* Previous history of influenza vaccination or documented history of influenza infection.
* Receipt of any vaccine in the 7 days prior to enrollment.
* An acute illness with fever (rectal temperature ≥ 38.0 °C \[or ≥ 100.4 °F\]) in the 72 hours preceding enrollment in the trial (defer enrollment).
* Known bleeding disorder.
* Participation in any other clinical trial within 30 days prior to enrollment, or planned participation in another clinical trial prior to termination of the subject's participation in this study.
* Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth.
* Personal or immediate family history of congenital immune deficiency.
* Developmental delay, neurologic disorder, or seizure disorder.
* Chronic medical, congenital or developmental disorder that could interfere with trial conduct or completion.
* Known HIV-positive or HBsAg-positive mother.
* Known HIV, hepatitis B (HBsAg), or hepatitis C infection.
* Blood or blood-derived products received in the past 2 months.
* Prior history of Guillain-Barré syndrome.
* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.
Short Course Radiation Therapy in Palliative Treatment of Thoracic Cancer

Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic thoracic malignant lesions

Standard treatment for thoracic lesions (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (2000 cGy in 4 fractions of 500 cGy twice a day) to demonstrate non-inferiority of this scheme

Eligibility Criteria:
Inclusion Criteria:

* symptomatic thoracic malignant lesions (primary solid tumors or metastases from solid tumor)
* age\> 18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3
* no changes in supportive care in the week before radiotherapy

Exclusion Criteria:

* pregnancy
* previous irradiation of the same region
Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer

The aim of the study is to evaluate the safety and efficacy of diosmin as adjuvant therapy in treatment of non-bleeding peptic ulcer patients.


Eligibility Criteria:
Inclusion Criteria:

-. Age 25-65 years old.

* Patients of both gender (male and female).
* Non-bleeding Peptic ulcer Patients (duodenal \&gastric) diagnosed by endoscopy.

Exclusion Criteria:

* The presence of other factors that can lead to gastric bleeding other than peptic ulcer.

  * Patients with cancerous disease
  * Breast-feeding.
  * Surgically altered stomach ( bariatric surgery),
  * Patient with liver disease.
* Bleeding \& perforated peptic ulcer.
The Use of 2D and 3D Imaging Modalities and Its Influence on Diagnosis and Treatment Planning in Orthodontics

Research questions:

1. Will the panoramic images derived from cone beam CT data give better diagnostic ability than conventional panoramic radiographs?
2. Will 3D cephalometric analysis offer the orthodontists and surgeons better information for treatment planning?
3. Will the 3D cephalometric analysis give more accurate treatment plan and better treatment outcome?

General hypothesis and special aims

Overall aims:

* To compare 2D versus 3D cephalometric analysis: treatment planning and therapeutic outcome.
* To determine the accuracy and diagnostic ability and usability of the 3D cephalometric analysis.
* To evaluate the diagnostic ability and usability of the panoramic image derived from cone beam CT data as compared to 2D panoramic images.
* To evaluate the value of the cone beam CT data in cephalometric analysing process for orthodontic and maxillofacial surgery treatment.

Hypotheses:

1. The availability of the 3D cephalometric analysis influences the orthodontic and maxillofacial treatment plan and decision, and might change the treatment outcome.
2. Panoramic images derived from cone beam CT data may provide equal information for diagnosis as conventional panoramic images.
3. Cone beam CT will be able to replace "classic orthodontic imaging" being more time and dose efficient and having a beneficial effect on treatment outcome.


Eligibility Criteria:
Inclusion Criteria:

* age 12-25 years old
* Patients with malocclusions
* Patients with jaw relation defect both with or without the need of orthognathic surgery
* Patients with maxillofacial defects: tumors and trauma
* Patients with eruption problems: embedded or impacted teeth which have to be removed

Exclusion Criteria:

* Patients with congenital deformities
* Patients with systemic diseases that may effect the growth formation: growth factor defect and thyroid hormone defect.
Geriatric Assessment at Discharge From the Intensive Care Unit in Patients Aged 75 Years and Older: a Feasibility Study

The number of patients aged over 75 continues to grow, and, according to INSEE, will represent almost 10% of the French population in 2021, an increase of 2.4 points since 2000. This demographic change is also observed in the intensive care units, where admitted patients aged over 80 represent now up to 10-20% of critical care admissions, depending on the facility.

The admission of these patients remains controversial, with questions about the benefit to elderly patients, both in terms of in-hospital and distant survival, as well as induced morbidity or subsequent quality of life: functional status is impaired in up to two-thirds of survivors.

The challenge of identifying the patients most able to withstand a stay is a major one. Indeed, a stay in intensive care represents a major stress for the organism, due to the acute condition associated with one or more organ failure(s). Bed rest, immobilization and the use of drugs are responsible for formidable complications in the elderly: muscle-wasting, loss of adaptation to physical effort, loss of autonomy, delirium and agitation, all of which have their own long-term impact.

While many studies have looked at the prognostic factors on admission of these patients, and the selection of the patient with the greatest probability of surviving the intensive care unit (ICU), improving the outcome of patients who survive to the ICU stay remains a little-investigated subject. However, the impact of physical and psychological disturbances induced by these patients' stay in intensive care is major, and their detection and management could be elements of interest in improving the care of this population. However, the feasibility of carrying out such an assessment immediately after an ICU stay has yet to be evaluated. The aim of this study would be to evaluate the feasibility of a geriatric assessment at the end of the ICU stay (or within 7 days of discharge) and at 6 months. This study is a prospective, randomized, single-center, open-label interventional study.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 75 years of age
* Admitted to the intensive care unit, for whatever reason, and having survived their stay, considered as leaving the intensive care unit.
* Subjects affiliated to a health insurance scheme
* Able to understand the aims and risks of the research and to give dated, signed informed consent,
* In the event of confusion on leaving the intensive care unit, a close relative available to give dated, signed informed consent, with the patient's consent collected as soon as his or her condition permits.

Exclusion Criteria:

* Protected subject as defined by law: safeguard of justice, guardianship or curatorship procedures
* Subject moribund, or whose life expectancy as estimated by the clinician in charge is less than 1 month
* Patient not living in Bas-Rhin (visit to M6)
Effects of Intralipid Versus Olive Oil Infusions on Endothelial Function, Immune Function, Inflammatory Markers

Recent evidence suggests that increased levels of a circulation fat (free fatty acids or FFAs) can cause high blood pressure and cardiac complications. Intralipid is the only type of fat approved by the FDA for clinical use. It is usually used as nutrition support in malnourished patients. The investigators' preliminary studies indicate that Intralipid results in a significant rise in blood pressure, blood vessel stiffness, and inflammation in obese subjects. Olive oil can also be used as nutrition support. The effect of olive oil intravenous (IV) on blood pressure and inflammation is not known. In this study, the investigators will compare the effect of Intralipid and olive oil on blood pressure, blood vessel stiffness and inflammation in healthy subjects. The investigators hypothesize that Olive oil emulsions will result in less vascular changes and less inflammatory response than Intralipid solutions. Accordingly, the investigators propose a systematic evaluation of the effects of Intralipid, olive oil and normal saline on blood pressure, endothelial function (vascular stiffness), inflammation in normal subjects.

A group of obese subjects will be admitted to the Clinical Research Center on 3 occasions. Subjects will receive repeated infusions of Intralipid, ClinOleic, and normal saline at 20 ml/hour for 24 hours.


Eligibility Criteria:
Inclusion Criteria:

* Healthy males or females
* BMI 25 -35 kg/m2, between the ages of 18 and 65 years
* BP \< 140/80 mm Hg and no prior history of hypertension

Exclusion Criteria:

* Pregnancy or breast feeding
* History of diabetes, hypertension, fasting triglyceride levels \> 250 mg/dL, liver disease (ALT 2.5x \> upper limit of normal), serum creatinine ≥ 1.5 mg/dL, -Smokers or ex-smoker \< 3 months of cessation, drug or alcohol abuse
* Mental condition rendering the subject unable to understand the scope and possible consequences of the study
Cognitive Stimulation Therapy - Effects on Cognitive and Functional Domains in Dementia - A Retrospective Data Review

This retrospective, single-blind, parallel group study investigates the efficacy of Cognitive Stimulation Therapy (CST) compared to Reality Orientation and Reminiscence Therapy (RO\&RM) in enhancing cognitive and functional domains in older adults with mild to moderate dementia.

Through data review, this retrospective, single-blind, parallel group study investigates the efficacy of Cognitive Stimulation Therapy (CST) compared to Reality Orientation and Reminiscence Therapy (RO\&RM) in enhancing cognitive and functional domains in older adults with mild to moderate dementia.

Eligibility Criteria:
Inclusion Criteria:

* participants had to be 65 years old or above, live in Hong Kong and had a diagnosis for dementia in medical history

Exclusion Criteria:

* any major neurological illness other than dementia, any psychiatric disorder or a known history of substance abuse.